Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Massacusetts General Hospital for Children, Boston, MA, USA.
Pediatr Rheumatol Online J. 2020 Apr 15;18(1):31. doi: 10.1186/s12969-020-00424-x.
Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome is the most common periodic fever syndrome in children. There is considerable heterogeneity in management strategies and a lack of evidence-based treatment guidelines. Consensus treatment plans (CTPs) are standardized treatment regimens that are derived based upon best available evidence and current treatment practices that are a way to enable comparative effectiveness studies to identify optimal therapy and are less costly to execute than randomized, double blind placebo controlled trials. The purpose of this project was to develop CTPs and response criteria for PFAPA.
The CARRA PFAPA Working Group is composed of pediatric rheumatologists, infectious disease specialists, allergists/immunologists and otolaryngologists. An extensive literature review was conducted followed by a survey to assess physician practice patterns. This was followed by virtual and in-person meetings between 2014 and 2018. Nominal group technique (NGT) was employed to develop CTPs, as well as inclusion criteria for entry into future treatment studies, and response criteria. Consensus required 80% agreement.
The PFAPA working group developed CTPs resulting in 4 different treatment arms: 1. Antipyretic, 2. Abortive (corticosteroids), 3. Prophylaxis (colchicine or cimetidine) and 4. Surgical (tonsillectomy). Consensus was obtained among CARRA members for those defining patient characteristics who qualify for participation in the CTP PFAPA study.
The goal is for the CTPs developed by our group to lead to future comparative effectiveness studies that will generate evidence-driven therapeutic guidelines for this periodic inflammatory disease.
周期性发热、口疮性口炎、咽炎和颈部淋巴结炎(PFAPA)综合征是儿童中最常见的周期性发热综合征。在管理策略方面存在相当大的异质性,并且缺乏基于证据的治疗指南。共识治疗计划(CTP)是基于最佳现有证据和当前治疗实践制定的标准化治疗方案,是进行比较疗效研究以确定最佳治疗方法的一种方式,并且比随机、双盲安慰剂对照试验执行成本更低。本项目的目的是制定 PFAPA 的 CTP 和反应标准。
CARRA PFAPA 工作组由儿科风湿病学家、传染病专家、过敏症/免疫学家和耳鼻喉科医生组成。进行了广泛的文献回顾,随后进行了一项调查,以评估医生的实践模式。之后在 2014 年至 2018 年期间进行了虚拟和现场会议。名义小组技术(NGT)用于制定 CTP,以及进入未来治疗研究的纳入标准和反应标准。共识需要 80%的同意。
PFAPA 工作组制定了 CTP,导致了 4 种不同的治疗方案:1. 退热,2. 发作性(皮质类固醇),3. 预防(秋水仙碱或西咪替丁)和 4. 手术(扁桃体切除术)。CARRA 成员就那些符合 CTP PFAPA 研究参与资格的定义患者特征达成了共识。
我们小组制定的 CTP 的目标是进行未来的比较疗效研究,为这种周期性炎症性疾病生成循证治疗指南。